CA3025178A1 - Callyspongiolide, analogs thereof and uses thereof - Google Patents

Callyspongiolide, analogs thereof and uses thereof Download PDF

Info

Publication number
CA3025178A1
CA3025178A1 CA3025178A CA3025178A CA3025178A1 CA 3025178 A1 CA3025178 A1 CA 3025178A1 CA 3025178 A CA3025178 A CA 3025178A CA 3025178 A CA3025178 A CA 3025178A CA 3025178 A1 CA3025178 A1 CA 3025178A1
Authority
CA
Canada
Prior art keywords
compound
formula
alkyl
mmol
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3025178A
Other languages
English (en)
French (fr)
Inventor
Arun K. Ghosh
Luke A. KASSEKERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CA3025178A1 publication Critical patent/CA3025178A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA3025178A 2016-05-27 2017-05-26 Callyspongiolide, analogs thereof and uses thereof Pending CA3025178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342601P 2016-05-27 2016-05-27
US62/342,601 2016-05-27
PCT/US2017/034760 WO2017205791A1 (en) 2016-05-27 2017-05-26 Callyspongiolide, analogs thereof and uses thereof

Publications (1)

Publication Number Publication Date
CA3025178A1 true CA3025178A1 (en) 2017-11-30

Family

ID=60411563

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025178A Pending CA3025178A1 (en) 2016-05-27 2017-05-26 Callyspongiolide, analogs thereof and uses thereof

Country Status (7)

Country Link
US (1) US10875836B2 (enExample)
EP (1) EP3463579B1 (enExample)
JP (3) JP7502846B2 (enExample)
KR (1) KR102481799B1 (enExample)
CN (2) CN118812488A (enExample)
CA (1) CA3025178A1 (enExample)
WO (1) WO2017205791A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118812488A (zh) 2016-05-27 2024-10-22 普渡研究基金会 美丽海绵内酯、其类似物及其用途
WO2024021261A1 (zh) * 2022-07-29 2024-02-01 上海皓元医药股份有限公司 一种艾日布林中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104177209B (zh) * 2014-08-05 2015-12-02 太原理工大学 一种芳基末端炔的制备方法
CN105777702B (zh) * 2016-03-31 2018-02-13 北京大学深圳研究生院 Callyspongiolide立体异构体的合成及抗癌应用
CN118812488A (zh) 2016-05-27 2024-10-22 普渡研究基金会 美丽海绵内酯、其类似物及其用途

Also Published As

Publication number Publication date
JP2024164181A (ja) 2024-11-26
JP7641933B2 (ja) 2025-03-07
US20190218198A1 (en) 2019-07-18
KR20190012194A (ko) 2019-02-08
CN118812488A (zh) 2024-10-22
JP2022120170A (ja) 2022-08-17
JP2019517474A (ja) 2019-06-24
EP3463579A4 (en) 2019-11-27
KR102481799B1 (ko) 2022-12-26
EP3463579B1 (en) 2025-07-16
WO2017205791A1 (en) 2017-11-30
CN109195666A (zh) 2019-01-11
US10875836B2 (en) 2020-12-29
JP7502846B2 (ja) 2024-06-19
EP3463579A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
AU2020294781B2 (en) Compounds for treatment of PD-L1 diseases
US8946289B2 (en) Manassatin compounds and methods of making and using the same
EP3142659B1 (en) Hiv-1 protease inhibitors and uses thereof
CA3097063A1 (en) Magl inhibitors
JP2024164181A (ja) カリスポンジオリド、その類似体、およびそれらの使用
EP3675848A1 (en) Spirocycle compounds and methods of making and using same
CA3082735A1 (en) Substituted macrocyclic indole derivatives
WO2018089621A1 (en) Tricyclic p2-ligand containing potent hiv-protease inhibitors against hiv/aids
CA2982564C (en) Epoxyazulene derivatives useful for treating cancer
US11230550B2 (en) Macrocyclic HIV-1 protease inhibitors and uses thereof
US11851441B2 (en) Anti-cancer agents and preparation thereof
EP4121042A1 (en) Tricyclic p2-ligand containing potent hiv-protease inhibitors
CA3068980A1 (en) Englerin derivatives for treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526

EEER Examination request

Effective date: 20220526